

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010;127:2893–2917.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013;63:11–30.
3. Lipsky MJ, Deibert CM, McKiernan JM. Epidemiology, screening, and clinical staging. In: Libertino JA, ed. *Renal Cancer: Contemporary Management*. New York: Springer Science + Business Media; 2013:1–18.
4. Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma-age and stage characterization and clinical implications: study of 1092 patients (1982–1997). *Urology* 2000;56:58–62.
5. Decastro GJ, McKiernan JM. Epidemiology, clinical staging, and presentation of renal cell carcinoma. *Urol Clin North Am* 2008;35:581–592; vi.
6. Kummerlin IP, ten Kate FJ, Wijkstra H, et al. Changes in the stage and surgical management of renal tumours during 1995–2005: an analysis of the Dutch national histopathology registry. *BJU Int* 2008;102:946–951.
7. Verhoest G, Veillard D, Guille F, et al. Relationship between age at diagnosis and clinicopathologic features of renal cell carcinoma. *Eur Urol* 2007;51:1298–1304; discussion 1304–1305.
8. Stafford HS, Saltzstein SL, Shimasaki S, et al. Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. *J Urol* 2008;179:1704–1708.
9. Ljungberg B, Campbell SC, Cho HY, et al. The epidemiology of renal cell carcinoma. *Eur Urol* 2011;60:615–621.
10. Hunt JD, van der Hel OL, McMillan GP, et al. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. *Int J Cancer* 2005;114:101–108.
11. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet* 2008;371:569–578.
12. Grossman E, Messerli FH, Boyko V, et al. Is there an association between hypertension and cancer mortality? *Am J Med* 2002;112:479–486.
13. Grossman E, Messerli FH, Goldbourt U. Antihypertensive therapy and the risk of malignancies. *Eur Heart J* 2001;22:1343–1352.
14. Cho E, Curhan G, Hankinson SE, et al. Prospective evaluation of analgesic use and risk of renal cell cancer. *Arch Intern Med* 2011;171:1487–1493.
15. Mihara S, Kuroda K, Yoshioka R, et al. Early detection of renal cell carcinoma by ultrasonographic screening—based on the results of 13 years screening in Japan. *Ultrasound Med Biol* 1999;25:1033–1039.
16. Algaba F, Akaza H, Lopez-Beltran A, et al. Current pathology keys of renal cell carcinoma. *Eur Urol* 2011;60:634–643.
17. Deng F-M, Melamed J, Zhou M. Pathology of renal cell carcinoma. In: Libertino JA, ed. *Renal Cancer: Contemporary Management*. New York: Springer Science + Business Media; 2013:51–69.
18. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. *Am J Surg Pathol* 1982;6:655–663.
19. Chevillet JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. *Am J Surg Pathol* 2003;27:612–624.
20. Kang SK, Chandarana H. Contemporary imaging of the renal mass. *Urol Clin North Am* 2012;39:161–170.
21. Divgi CR, Uzzo RG, Gatsonis C, et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. *J Clin Oncol* 2013;31:187–194.
22. Bosniak MA. The Bosniak renal cyst classification: 25 years later. *Radiology* 2012;262:781–785.
23. Corcoran AT, Russo P, Lowrance WT, et al. A review of contemporary data on surgically resected renal masses—benign or malignant? *Urology* 2013;81:707–713.
24. Lane BR, Babineau D, Kattan MW, et al. A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. *J Urol* 2007;178:429–434.
25. Lane BR, Aydin H, Danforth TL, et al. Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioid. *J Urol* 2008;180:836–843.
26. Eggener SE, Rubenstein JN, Smith ND, et al. Renal tumors in young adults. *J Urol* 2004;171:106–110.
27. Frank I, Blute ML, Chevillet JC, et al. Solid renal tumors: an analysis of pathological features related to tumor size. *J Urol* 2003;170:2217–2220.
28. Kutikov A, Smailovic MC, Egleston BL, et al. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. *Eur Urol* 2011;60:241–248.
29. Halverson SJ, Kunju LP, Bhalla R, et al. Accuracy of determining small renal mass management with risk stratified biopsies: confirmation by final pathology. *J Urol* 2013;189:441–446.
30. Lane BR, Samplaski MK, Herts BR, et al. Renal mass biopsy—a renaissance? *J Urol* 2008;179:20–27.
31. Samplaski MK, Zhou M, Lane BR, et al. Renal mass sampling: an enlightened perspective. *Int J Urol* 2011;18:5–19.
32. Leveridge M, Musquera M, Evans A, et al. Renal cell carcinoma in the native and allograft kidneys of renal transplant recipients. *J Urol* 2011;186:219–223.
33. Schmidbauer J, Remzi M, Memarsadeghi M, et al. Diagnostic accuracy of computed tomography-guided percutaneous biopsy of renal masses. *Eur Urol* 2008;53:1003–1011.
34. Volpe A, Finelli A, Gill IS, et al. Rationale for percutaneous biopsy and histologic characterisation of renal tumours. *Eur Urol* 2012;62:491–504.
35. Edge SB, Byrd DR, Compton CC. *AJCC Cancer Staging Manual*. Vol 7. New York, NY: Springer; 2010.
36. Meskawi M, Sun M, Trinh QD, et al. A review of integrated staging systems for renal cell carcinoma. *Eur Urol* 2012;62:303–314.
37. Linehan WM, Pinto PA, Bratslavsky G, et al. Hereditary kidney cancer: unique opportunity for disease-based therapy. *Cancer* 2009;115:2252–2261.
38. Linehan WM, Ricketts CJ. The metabolic basis of kidney cancer. *Semin Cancer Biol* 2013;23:46–55.
39. Shuch B, Pinto P. Familial and hereditary syndromes. In: Libertino JA, ed. *Renal Cancer: Contemporary Management*. New York: Springer Science + Business Media; 2013:39–50.
40. Keefe SM, Nathanson KL, Rathmell WK. The molecular biology of renal cell carcinoma. *Semin Oncol* 2013;40:421–428.
41. Jonasch E, Futreal PA, Davis IJ, et al. State of the science: an update on renal cell carcinoma. *Mol Cancer Res* 2012;10:859–880.
42. Klomp J, Dykema K, Teh BT, et al. Molecular biology and genetics. In: Libertino JA, ed. *Renal Cancer: Contemporary Management*. New York: Springer Science + Business Media; 2013:19–37.
43. Zhao Q, Caballero OL, Davis ID, et al. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. *Clin Cancer Res* 2013;19:2460–2472.
44. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature* 2013;499:43–49.
45. Chen F, Kishida T, Yao M, et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. *Hum Mutat* 1995;5:66–75.
46. Shuch B, Singer EA, Bratslavsky G. The surgical approach to multifocal renal cancers: hereditary syndromes, ipsilateral multifocality, and bilateral tumors. *Urol Clin North Am* 2012;39:133–148, v.
47. Bottaro DP, Rubin JS, Faleto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. *Science* 1991;251:802–804.
48. Ooi A, Wong JC, Petillo D, et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. *Cancer Cell* 2011;20:511–523.
49. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. *J Urol* 2006;176:2353–2358.
50. Miller DC, Ruterbusch J, Colt JS, et al. Contemporary clinical epidemiology of renal cell carcinoma: insight from a population based case-control study. *J Urol* 2010;184:2254–2258.
51. Silverman SG, Israel GM, Herts BR, et al. Management of the incidental renal mass. *Radiology* 2008;249:16–31.
52. Aron M, Gill IS, Boorjian SA, et al. Treatment of the 2 to 3 cm renal mass. *J Urol* 2010;184:419–422.
53. Campbell SC, Thomas AA, Rini BI, et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. *J Urol* 2009;181:518–523.
54. Kim SP, Thompson RH. Approach to the small renal mass: to treat or not to treat. *Urol Clin North Am* 2012;39(2):171–179.
55. Kunkle DA, Chen DYT, Greenberg RE, et al. Metastatic progression of enhancing renal masses under active surveillance is associated with rapid interval growth of the primary tumor. *J Urol* 2008;179(4 Suppl):375.
56. Van Poppel H, Becker F, Cadeddu JA, et al. Treatment of localised renal cell carcinoma. *Eur Urol* 2011;60:662–672.
57. Volpe A, Cadeddu JA, Cestari A, et al. Contemporary management of small renal masses. *Eur Urol* 2011;60:501–515.
58. Russo P, Huang W. The medical and oncological rationale for partial nephrectomy for the treatment of T1 renal cortical tumors. *Urol Clin North Am* 2008;35:635–643; vii.
59. Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. *Eur Urol* 2011;59:543–552.
60. Tan HJ, Norton EC, Ye Z, et al. Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. *JAMA* 2012;307:1629–1635.
61. Tobert CM, Riedinger CB, Lane BR. Do we know (or just believe) that partial nephrectomy leads to better survival than radical nephrectomy for renal cancer? *World J Urol* 2014 (Epub ahead of print).
62. Kim SP, Thompson RH, Boorjian SA, et al. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. *J Urol* 2012;188:51–57.
63. Campbell DE, Tustin NB, Riedel E, et al. Cryopreservation decreases receptor PD-1 and ligand PD-L1 coinhibitory expression on peripheral blood mononuclear cell-derived T cells and monocytes. *Clin Vaccine Immunol* 2009;16:1648–1653.

64. Ljungberg B, Grankvist K, Rasmuson T. Serum acute phase reactants and prognosis in renal cell carcinoma. *Cancer* 1995;76:1435–1439.
65. Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. *Eur Urol* 2010;58:398–406.
66. Ljungberg B, Hanbury DC, Kuczyk MA, et al. Renal cell carcinoma guideline. *Eur Urol* 2007;51:1502–1510.
67. Campbell SC, Novick AC, Belldgrun A, et al. Guideline for management of the clinical T1 renal mass. *J Urol* 2009;182:1271–1279.
68. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. *J Urol* 1969;101:297–301.
69. Lam JS, Klatte T, Patard JJ, et al. Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. *Eur Urol* 2007;52:155–162.
70. Thompson RH, Blute ML, Krambeck AE, et al. Patients with pT1 renal cell carcinoma who die from disease after nephrectomy may have unrecognized renal sinus fat invasion. *Am J Surg Pathol* 2007;31:1089–1093.
71. Bratslavsky G, Linehan WM. Surgery: Routine adrenalectomy in renal cancer—an antiquated practice. *Nat Rev Urol* 2011;8:534–536.
72. Lane BR, Tiong HY, Campbell SC, et al. Management of the adrenal gland during partial nephrectomy. *J Urol* 2009;181:2430–2437.
73. Weight CJ, Kim SP, Lohse CM, et al. Routine adrenalectomy in patients with locally advanced renal cell cancer does not offer oncologic benefit and places a significant portion of patients at risk for an asynchronous metastasis in a solitary adrenal gland. *Eur Urol* 2011;60:458–464.
74. Blom JH, van Poppel H, Marechal JM, et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. *Eur Urol* 2009;55:28–34.
75. Leibovich BC, Blute ML. Lymph node dissection in the management of renal cell carcinoma. *Urol Clin North Am* 2008;35:673–678; viii.
76. Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. *J Clin Oncol* 2005;23:2763–2771.
77. Phillips CK, Taneja SS. The role of lymphadenectomy in the surgical management of renal cell carcinoma. *Urol Oncol* 2004;22:214–224.
78. Nguyen CT, Campbell SC. Salvage of local recurrence after primary thermal ablation for small renal masses. *Expert Rev Anticancer Ther* 2008;8:1899–1905.
79. Diblasio CJ, Snyder ME, Russo P. Mini-flank supra-11th rib incision for open partial or radical nephrectomy. *BJU Int* 2006;97:149–156.
80. Chung SD, Chueh SC, Lai MK, et al. Long-term outcome of hand-assisted laparoscopic radical nephroureterectomy for upper-tract urothelial carcinoma: comparison with open surgery. *J Endourol* 2007;21:595–599.
81. Kawachi A, Yoneda K, Fujito A, et al. Oncologic outcome of hand-assisted laparoscopic radical nephrectomy. *Urology* 2007;69:53–56.
82. Miyake H, Hara I, Nakano Y, et al. Hand-assisted laparoscopic radical nephrectomy: comparison with conventional open radical nephrectomy. *J Endourol* 2007;21:429–432.
83. Nadler RB, Loeb S, Clemens JQ, et al. A prospective study of laparoscopic radical nephrectomy for T1 tumors—is transperitoneal, retroperitoneal or hand assisted the best approach? *J Urol* 2006;175:1230–1234.
84. Nakada SY. Surgical removal of small renal tumors—going, going, gone? *J Urol* 2005;174:9.
85. Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. *Lancet Oncol* 2006;7:735–740.
86. Lane BR, Russo P, Uzzo RG, et al. Comparison of cold and warm ischemia during partial nephrectomy in 660 solitary kidneys reveals predominant role of nonmodifiable factors in determining ultimate renal function. *J Urol* 2011;185:421–427.
87. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med* 2004;351:1296–1305.
88. Huang WC, Elkin EB, Levey AS, et al. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors—is there a difference in mortality and cardiovascular outcomes? *J Urol* 2009;181:55–62.
89. Miller DC, Schonlau M, Litwin MS, et al. Renal and cardiovascular morbidity after partial or radical nephrectomy. *Cancer* 2008;112:511–520.
90. Thompson RH, Boorjian SA, Lohse CM, et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. *J Urol* 2008;179:468–471; discussion 472–473.
91. Herr HW. A history of partial nephrectomy for renal tumors. *J Urol* 2005;173:705–708.
92. Vermooten V. Indications for conservative surgery in certain renal tumors: a study based on the growth pattern of the cell carcinoma. *J Urol* 1950;64:200–208.
93. Chow WH, Shuch B, Linehan WM, et al. Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics. *Cancer* 2013;119:388–394.
94. Lane BR, Kattan MW. Prognostic models and algorithms in renal cell carcinoma. *Urol Clin North Am* 2008;35:613–625.
95. Uzzo RG, Novick AC. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. *J Urol* 2001;166:6–18.
96. Campbell SC, Novick AC, Strem SB, et al. Management of renal cell carcinoma with coexistent renal artery disease. *J Urol* 1993;150:808–813.
97. Hafez KS, Krishnamurthi V, Campbell SC, et al. Contemporary management of renal cell carcinoma with coexistent renal artery disease: update of the Cleveland Clinic experience. *Urology* 2000;56:382–386.
98. Breaux RH, Crispin PL, Jimenez RE, et al. Outcome of stage T2 or greater renal cell cancer treated with partial nephrectomy. *J Urol* 2010;183:903–908.
99. Long CJ, Canter DJ, Kutikov A, et al. Partial nephrectomy for renal masses  $\geq 7$  cm: technical, oncological and functional outcomes. *BJU Int* 2012;109:1450–1456.
100. Kopp RP, Mehraraz R, Palazzi KL, et al. Survival outcomes after radical and partial nephrectomy for clinical T2 renal tumors categorized by RENAL nephrometry score. *BJU Int* 2013 (Epub ahead of print).
101. Lane BR, Golan S, Eggener S, et al. Differential use of partial nephrectomy for intermediate and high complexity tumors may explain variability in reported utilization rates. *J Urol* 2013;189:2047–2053.
102. Lane BR, Fergany AF, Linehan WM, et al. Should preservable parenchyma, and not tumor size, be the main determinant of the feasibility of partial nephrectomy? *Urology* 2010;76:608–609.
103. Fergany AF, Hafez KS, Novick AC. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. *J Urol* 2000;163:442.
104. Lane BR, Campbell SC, Gill IS. Ten-year oncologic outcomes after laparoscopic and open partial nephrectomy. *J Urol* 2013;190:44–49.
105. Lane BR, Fergany AF, Weight CJ, et al. Renal functional outcomes after partial nephrectomy with extended ischemic intervals are better than after radical nephrectomy. *J Urol* 2010;184:1286–1290.
106. Fergany AF, Saad IR, Woo L, et al. Open partial nephrectomy for tumor in a solitary kidney: experience with 400 cases. *J Urol* 2006;175:1630–1633.
107. Ghavamian R, Chevillat JC, Lohse CM, et al. Renal cell carcinoma in the solitary kidney: an analysis of complications and outcome after nephron sparing surgery. *J Urol* 2002;168:454–459.
108. Gorin MA, Ekwenna O, Soloway MS, et al. Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery. *Urology* 2012;79:e11.
109. Kroon BK, de Bruijn R, Prevoo W, et al. Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation. *Urology* 2013;81:111–115.
110. Thomas AA, Rini BI, Campbell SC. Integration of surgery and systemic therapy in the management of metastatic renal cancer. *Curr Urol Rep* 2009;10:35–41.
111. Lane BR, Derweesh IH, Kim HL, et al. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. *Urology* (In press).
112. Bensalah K, Pantuck AJ, Rioux-Leclercq N, et al. Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. *Eur Urol* 2010;57:466–471.
113. Bernhard JC, Pantuck AJ, Wallerand H, et al. Predictive factors for ipsilateral recurrence after nephron-sparing surgery in renal cell carcinoma. *Eur Urol* 2010;57:1080–1086.
114. Li QL, Cheng L, Guan HW, et al. Safety and efficacy of mini-margin nephron-sparing surgery for renal cell carcinoma 4-cm or less. *Urology* 2008;71:924–927.
115. Marszalek M, Carini M, Chlosta P, et al. Positive surgical margins after nephron-sparing surgery. *Eur Urol* 2012;61:757–763.
116. Sundaram V, Figenschau RS, Rojzman TM, et al. Positive margin during partial nephrectomy: does cancer remain in the renal remnant? *Urology* 2011;77:1400–1403.
117. Yossepowitch O, Thompson RH, Leibovich BC, et al. Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. *J Urol* 2008;179:2158–2163.
118. Lane BR, Gill IS. Five year outcomes of laparoscopic partial nephrectomy. *J Urol* 2007;177:70–74.
119. Gill IS, Kavoussi LR, Lane BR, et al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. *J Urol* 2007;178:41–46.
120. Dulabon LM, Kaouk JH, Haber GP, et al. Multi-institutional analysis of robotic partial nephrectomy for hilar versus nonhilar lesions in 446 consecutive cases. *Eur Urol* 2011;59:325–330.
121. Gill IS, Kamoi K, Aron M, et al. 800 Laparoscopic partial nephrectomies: a single surgeon series. *J Urol* 2010;183:34–41.
122. Kaouk JH, Hillyer SP, Autorino R, et al. 252 robotic partial nephrectomies: Evolving renorrhaphy technique and surgical outcomes at a single institution. *Urology* 2011;78:1338–1344.
123. Kaouk JH, Khalifeh A, Hillyer S, et al. Robot-assisted laparoscopic partial nephrectomy: step-by-step contemporary technique and surgical outcomes at a single high-volume institution. *Eur Urol* 2012;62:553–561.
124. Mullins JK, Feng T, Pierorazio PM, et al. Comparative analysis of minimally invasive partial nephrectomy techniques in the treatment of localized renal tumors. *Urology* 2012;80:316–321.
125. Tuma B, Kaouk JH, Frota R, et al. Minimally invasive nephron sparing management for renal tumors in solitary kidneys. *J Urol* 2009;182:2150–2157.
126. Simhan J, Smaldone MC, Tsai KJ, et al. Perioperative outcomes of robotic and open partial nephrectomy for moderately and highly complex renal lesions. *J Urol* 2012;187:2000–2004.

127. Murphy DP, Gill IS. Energy-based renal tumor ablation: a review. *Semin Urol Oncol* 2001;19:133–140.
128. Sterrett SP, Nakada SY, Wingo MS, et al. Renal thermal ablative therapy. *Urol Clin North Am* 2008;35:397–414, viii.
129. Johnson DB, Solomon SB, Su LM, et al. Defining the complications of cryoablation and radio frequency ablation of small renal tumors: a multi-institutional review. *J Urol* 2004;172:874–877.
130. Faddegon S, Caddeu JA. Does renal mass ablation provide adequate long-term oncologic control? *Urol Clin North Am* 2012;39:181–190.
131. Matin SF, Ahrar K. Management of small renal masses: energy-ablative therapy for small renal masses. In: Campbell SC, Rini BI, eds. *Renal Cell Carcinoma*. Vol 1. Shelton, CT: People's Medical Publishing House; 2009:81–94.
132. Atwell TD, Schmit GD, Boorjian SA, et al. Percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation. *AJR Am J Roentgenol* 2013;200:461–466.
133. del Cura JL, Zabala R, Iriarte JJ, et al. Treatment of renal tumors by percutaneous ultrasound-guided radiofrequency ablation using a multitined electrode: effectiveness and complications. *Eur Urol* 2010;57:459–465.
134. Tanagho YS, Royzman TM, Bhayani SB, et al. Laparoscopic cryoablation of renal masses: single-center long-term experience. *Urology* 2012;80:307–314.
135. Tracy CR, Raman JD, Donnally C, et al. Durable oncologic outcomes after radiofrequency ablation: experience from treating 243 small renal masses over 7.5 years. *Cancer* 2010;116:3135–3142.
136. Campbell SC, Palese MA. Laparoscopic cryoablation for a 3 cm nonhilar renal tumor. *J Urol* 2011;185:14–16.
137. Gill IS, Remer EM, Hasan WA, et al. Renal cryoablation: outcome at 3 years. *J Urol* 2005;173:1903–1907.
138. Guillotreau J, Haber GP, Autorino R, et al. Robotic partial nephrectomy versus laparoscopic cryoablation for the small renal mass. *Eur Urol* 2012;61:899–904.
139. Klatt T, Grubmuller B, Waldert M, et al. Laparoscopic cryoablation versus partial nephrectomy for the treatment of small renal masses: systematic review and cumulative analysis of observational studies. *Eur Urol* 2011;60:435–443.
140. Stein RJ, Kaouk JH. Renal cryotherapy: a detailed review including a 5-year follow-up. *BJU Int* 2007;99:1265–1270.
141. Bolte SL, Ankem MK, Moon TD, et al. Magnetic resonance imaging findings after laparoscopic renal cryoablation. *Urology* 2006;67:485–489.
142. Weight CJ, Kaouk JH, Hegarty NJ, et al. Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumors. *J Urol* 2008;179:1277–1281.
143. Donat SM, Diaz M, Bishoff JT, et al. Follow-up for clinically localized renal neoplasms: AUA guideline. *J Urol* 2013;190:407–416.
144. Lusch A, Gravarsen JA, Liss MA, et al. Ablative techniques: Radiofrequency and cryotherapy, which is the best? *Archivos Espanoles de Urologia* 2013;66:71–78.
145. Schmit GD, Thompson RH, Kurup AN, et al. Usefulness of R.E.N.A.L. nephrometry scoring system for predicting outcomes and complications of percutaneous ablation of 751 renal tumors. *J Urol* 2013;189:30–35.
146. Matin SF. Determining failure after renal ablative therapy for renal cell carcinoma: false-negative and false-positive imaging findings. *Urology* 2010;75:1254–1257.
147. Samarasekera D, Khalifeh A, Autorino R, et al. Percutaneous radiofrequency ablation versus percutaneous cryoablation: Long-term outcomes following ablation for renal cell carcinoma. *J Urol* 2013:Abstract 1795.
148. Haber GP, Crouzet S, Remer EM, et al. Stereotactic percutaneous cryoablation for renal tumors: initial clinical experience. *J Urol* 2010;183:884–888.
149. Kroeze SC, Grimbergen MC, Rehmann H, et al. Photodynamic therapy as novel nephron sparing treatment option for small renal masses. *J Urol* 2012;187:289–295.
150. Ponsky LE, Mahadevan A, Gill IS, et al. Renal radiosurgery: initial clinical experience with histological evaluation. *Surg Innov* 2007;14:265–269.
151. Castle SM, Salas N, Leveillee RJ. Initial experience using microwave ablation therapy for renal tumor treatment: 18-month follow-up. *Urology* 2011;77:792–797.
152. Lane BR, Tobert CM, Riedinger CB. Growth kinetics and active surveillance for small renal masses. *Curr Opin Urol* 2012;22:353–359.
153. Lane BR, Abouassaly R, Gao T, et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. *Cancer* 2010;116:3119–3126.
154. Corcoran AT, Russo P, Lowrance WT, et al. A review of contemporary data on surgically resected renal masses—benign or malignant? *Urology* 2013;81:707–713.
155. Smaldone MC, Kutikov A, Egleston BL, et al. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. *Cancer* 2012;118:997–1006.
156. Crispin PL, Soljac A, Stewart G, et al. Enhancing renal tumors in patients with prior normal abdominal imaging: further insight into the natural history of renal cell carcinoma. *J Urol* 2012;188:1089–1094.
157. Wotkowicz C, Wszolek MF, Libertino JA. Resection of renal tumors invading the vena cava. *Urol Clin North Am* 2008;35:657–671, viii.
158. Gettman MT, Blute ML. Update on pathologic staging of renal cell carcinoma. *Urology* 2002;60:209–217.
159. Sosa RE, Muecke EC, Vaughan ED Jr, et al. Renal cell carcinoma extending into the inferior vena cava: the prognostic significance of the level of vena caval involvement. *J Urol* 1984;132:1097–1100.
160. Quek ML, Stein JP, Skinner DG. Surgical approaches to venous tumor thrombus. *Semin Urol Oncol* 2001;19:88–97.
161. Zisman A, Wieder JA, Pantuck AJ, et al. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. *J Urol* 2003;169:909–916.
162. Leibovich BC, Cheville JC, Lohse CM, et al. Cancer specific survival for patients with pT3 renal cell carcinoma—can the 2002 primary tumor classification be improved? *J Urol* 2005;173:716–719.
163. Terakawa T, Miyake H, Takenaka A, et al. Clinical outcome of surgical management for patients with renal cell carcinoma involving the inferior vena cava. *Int J Urol* 2007;14:781–784.
164. Blute ML, Leibovich BC, Cheville JC, et al. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. *J Urol* 2004;172:465–469.
165. Libertino JA, Zimman L, Watkins E Jr. Long-term results of resection of renal cell cancer with extension into inferior vena cava. *J Urol* 1987;137:21–24.
166. Ciancio G, Livingstone AS, Soloway M. Surgical management of renal cell carcinoma with tumor thrombus in the renal and inferior vena cava: the University of Miami experience in using liver transplantation techniques. *Eur Urol* 2007;51:988–994; discussion 994–995.
167. Glazer AA, Novick AC. Long-term followup after surgical treatment for renal cell carcinoma extending into the right atrium. *J Urol* 1996;155:448–450.
168. Granberg CF, Boorjian SA, Schaff HV, et al. Surgical management, complications, and outcome of radical nephrectomy with inferior vena cava tumor thrombectomy facilitated by vascular bypass. *Urology* 2008;72:148–152.
169. Spiess PE, Kurian T, Lin HY, et al. Preoperative metastatic status, level of thrombus and body mass index predict overall survival in patients undergoing nephrectomy and inferior vena cava thrombectomy. *BJU Int* 2012;110:E470–E474.
170. Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. *J Urol* 2009;182:844–853.
171. Tilki D, Nguyen HG, Dall'era MA, et al. Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus. *Eur Urol* (Epub ahead of print).
172. Shuch B, Said J, La Rochelle JC, et al. Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology—is up-front resection indicated and, if not, is it avoidable? *J Urol* 2009;182:2164–2171.
173. Ciancio G, Gonzalez J, Shirodkar SP, et al. Liver transplantation techniques for the surgical management of renal cell carcinoma with tumor thrombus in the inferior vena cava: step-by-step description. *Eur Urol* 2011;59:401–406.
174. Slaton JW, Balbay MD, Levy DA, et al. Nephrectomy and vena caval thrombectomy in patients with metastatic renal cell carcinoma. *Urology* 1997;50:673–677.
175. Culp SH, Tannir NM, Abel EJ, et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? *Cancer* 2010;116:3378–3388.
176. Margulis V, Master VA, Cost NC, et al. International consultation on urologic diseases and the European Association of Urology international consultation on locally advanced renal cell carcinoma. *Eur Urol* 2011;60:673–683.
177. Crispin PL, Breaux RH, Allmer C, et al. Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. *Eur Urol* 2011;59:18–23.
178. Capitano U, Abdollah F, Matloob R, et al. When to perform lymph node dissection in patients with renal cell carcinoma: a novel approach to the preoperative assessment of risk of lymph node invasion at surgery and of lymph node progression during follow-up. *BJU Int* 2013;112:E59–E66.
179. Smaldone MC, Fung C, Uzzo RG, et al. Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma. *Hematol Oncol Clin North Am* 2011;25:765–791.
180. Motzer RJ, Agarwal N, Beard C, et al. Kidney cancer. *J Natl Compr Canc Netw* 2011;9:960–977.
181. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. *N Engl J Med* 2001;345:1655–1659.
182. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. *J Urol* 2004;171:1071–1076.
183. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. *Lancet* 2001;358:966–970.
184. Polcari AJ, Gorboson A, Milner JE, et al. The role of cytoreductive nephrectomy in the era of molecular targeted therapy. *Int J Urol* 2009;16:227–233.
185. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. *J Urol* 2004;171:1071–1076.
186. Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. *J Urol* 2011;185:60–66.

187. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results From a large, multicenter study. *J Clin Oncol* 2009;27:5794–5799.
188. Kassouf W, Sanchez-Ortiz R, Tamboli P, et al. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience. *Urology* 2007;69:835–838.
189. Kaushik D, Linder BJ, Thompson RH, et al. The impact of histology on clinicopathologic outcomes for patients with renal cell carcinoma and venous tumor thrombus: a matched cohort analysis. *Urology* 2013;82:136–141.
190. Choueiri TK. Clinical treatment decisions for advanced renal cell cancer. *J Natl Compr Canc Netw* 2013;11:694–697.
191. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *N Engl J Med* 2007;356:2271–2281.
192. Abdollah F, Sun M, Thuret R, et al. Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study. *Ann Surg Oncol* 2011;18:2988–2996.
193. Trinh QD, Bianchi M, Hansen J, et al. In-hospital mortality and failure to rescue after cytoreductive nephrectomy. *Eur Urol* 2013;63:1107–1114.
194. Kutikov A, Uzzo RG, Caraway A, et al. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. *BJU Int* 2010;106:218–223.
195. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. *J Urol* 2001;166:1611–1623.
196. Eggner SE, Yossepowitch O, Kundu S, et al. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. *J Urol* 2008;180:873–878; discussion 878.
197. Daliani DD, Tannir NM, Papatreou CN, et al. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. *BJU Int* 2009;104:456–460.
198. Middleton RG. Surgery for metastatic renal cell carcinoma. *J Urol* 1967;97:973–977.
199. van der Poel HC, Roukema JA, Horenblas S, et al. Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis. *Eur Urol* 1999;35:197–203.
200. Alt AL, Boorjian SA, Lohse CM, et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. *Cancer* 2011;117:2873–2882.
201. Pogrebnik HW, Haas G, Linehan WM, et al. Renal cell carcinoma: resection of solitary and multiple metastases. *Ann Thorac Surg* 1992;54:33–38.
202. Tanguay S, Swanson DA, Putnam JB Jr. Renal cell carcinoma metastatic to the lung: potential benefit in the combination of biological therapy and surgery. *J Urol* 1996;156:1586–1589.
203. Kim B, Louie AC. Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission. *Arch Surg* 1992;127:1343–1349.
204. Krishnamurthi V, Novick AC, Bukowski RM. Efficacy of multimodality therapy in advanced renal cell carcinoma. *Urology* 1998;51:933–937.
205. Sella A, Swanson DA, Ro JY, et al. Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma. *J Urol* 1993;149:19–21; discussion 21–22.
206. Sherry RM, Pass HI, Rosenberg SA, et al. Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. *Cancer* 1992;69:1850–1855.
207. Karam JA, Rini BI, Varella L, et al. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. *J Urol* 2011;185:439–444.
208. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. *Cancer Res* 1988;48:7310–7313.
209. Palmer PA, Vinke J, Philip T, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. *Ann Oncol* 1992;3:475–480.
210. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. *J Clin Oncol* 1999;17:2530–2540.
211. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. *J Clin Oncol* 2005;23:832–841.
212. de Forges A, Rey A, Klink M, et al. Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis. *Semin Surg Oncol* 1988;4:149–154.
213. Neves RJ, Zincke H, Taylor WF. Metastatic renal cell cancer and radical nephrectomy: identification of prognostic factors and patient survival. *J Urol* 1988;139:1173–1176.
214. Atzpodien J, Royston P, Wandert T, et al. Metastatic renal carcinoma comprehensive prognostic system. *Br J Cancer* 2003;88:348–353.
215. Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. *J Clin Oncol* 2002;20:2376–2381.
216. Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. *Cancer* 2003;97:1663–1671.
217. Lopez Hänninen E, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. *J Urol* 1996;155:19–25.
218. Fossa SD, Kramar A, Droz JP. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. *Eur J Cancer* 1994;30A:1310–1314.
219. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. *J Clin Oncol* 2002;20:289–296.
220. Rini BI. VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices. *Curr Oncol Rep* 2006;8:85–89.
221. Choueiri TK, Vaziri SA, Jaeger E, et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. *J Urol* 2008;180:860–865.
222. Choueiri TK, Fay AP, Gagnon R, et al. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. *Clin Cancer Res* 2013;19:5218–5226.
223. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. *Clin Cancer Res* 2003;9:802–811.
224. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. *Clin Cancer Res* 2005;11:3714–3721.
225. Clement JM, McDermott DF. The high-dose aldesleukin (IL-2) “select” trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma. *Clin Genitourin Cancer* 2009;7:E7–E9.
226. Xu CF, Bing NX, Ball HA, et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. *J Clin Oncol* 2011;29:2557–2564.
227. Garcia-Donas J, Esteban E, Leandro-Garcia LJ, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. *Lancet Oncol* 2011;12:1143–1150.
228. van Erp NP, Eechoute K, van der Veldt AA, et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. *J Clin Oncol* 2009;27:4406–4412.
229. Rini BI, Basappa NS, Elson P, et al. The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib. *Cancer* 2011;117:1183–1189.
230. Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. *J Natl Cancer Inst* 2011;103:763–773.
231. Dahlberg SE, Sandler AB, Brahmer JR, et al. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. *J Clin Oncol* 2010;28:949–954.
232. Papac RJ, Ross SA, Levy A. Renal cell carcinoma: analysis of 31 cases with assessment of endocrine therapy. *Am J Med Sci* 1977;274:281–290.
233. Pizzocaro G, Di Fronzo C, Cappelletti V, et al. Hormone treatment and sex steroid receptors in metastatic renal cell carcinoma: report of a multicentric prospective study. *Tumori* 1983;69:215–220.
234. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. *Lancet* 1999;353:14–17.
235. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. *Semin Oncol* 1995;22:42–60.
236. Buti S, Bersanelli M, Sikokis A, et al. Chemotherapy in metastatic renal cell carcinoma today? A systematic review. *Anticancer Drugs* 2013;24:535–554.
237. Rini BI, Weinberg V, Small EJ. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. *Cancer* 2005;103:553–558.
238. Stadler WM, Halabi S, Rini B, et al. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. *Cancer* 2006;107:1273–1279.
239. Fossa SD, Droz JP, Pavone-Macaluso MM, et al. Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group. *Eur J Cancer* 1992;28A:878–880.
240. Neidhart JA, Anderson SA, Harris JE, et al. Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. *J Clin Oncol* 1991;9:832–836.
241. Nanus DM, Garino A, Milowsky MI, et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. *Cancer* 2004;101:1545–1551.
242. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. *N Engl J Med* 1985;313:1485–1492.
243. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. *J Clin Oncol* 2005;23:133–141.

244. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. *J Clin Oncol* 2003;21:3127-3132.
245. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. *J Clin Oncol* 1995;13:688-696.
246. Fyfe GA, Fisher RI, Rosenberg SA, et al. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. *J Clin Oncol* 1996;14:2410-2411.
247. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. *Cancer J Sci Am* 2000;6:S55-S57.
248. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. *J Clin Oncol* 1999;17:2859-2867.
249. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. *N Engl J Med* 1998;338:1272-1278.
250. Escudier B, Chevreau C, Lasset C, et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Francais d'Immunotherapie. *J Clin Oncol* 1999;17:2039-2043.
251. Atzpodien J, Kirchner H, Illiger HJ, et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. *Br J Cancer* 2001;85:1130-1136.
252. Atzpodien J, Kirchner H, Jonas U, et al. Interleukin-2- and interferon alfa-2a-based immunotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). *J Clin Oncol* 2004;22:1188-1194.
253. Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. *Nat Med* 2012;18:1254-1261.
254. Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. *Clin Cancer Res* 2008;14:6674-6682.
255. Pal SK, Hu A, Figlin RA. A new age for vaccine therapy in renal cell carcinoma. *Cancer J* 2013;19:365-370.
256. McDermott DF, Drake CG, Sznol M, et al. Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC). *J Clin Oncol* 2012;30(15 Suppl):4505.
257. Topalian SL, Brahmer JR, Hodi FS, et al. Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. *J Clin Oncol* 2012;30(15 Suppl):CRA2509.
258. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. *Nature* 1992;359:843-845.
259. Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. *Mol Cancer Ther* 2003;2:471-478.
260. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. *Clin Cancer Res* 2003;9:327-337.
261. Motzer RJ, Dror Michaelson M, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. *J Clin Oncol* 2006;24:16-24.
262. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. *JAMA* 2006;295:2516-2524.
263. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. *N Engl J Med* 2007;356:115-124.
264. Motzer RJ, Hudes G, Wilding G, et al. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. *Clin Genitourin Cancer* 2009;7:28-33.
265. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. *N Engl J Med* 2013;369:722-731.
266. Lyons JF, Wilhelm S, Hibner B, et al. Discovery of a novel Raf kinase inhibitor. *Endocr Relat Cancer* 2001;8:219-225.
267. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. *Cancer Res* 2004;64:7099-7109.
268. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. *J Clin Oncol* 2006;24:2505-2512.
269. Bukowski R, Cella D, Gondek K, et al. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. *Am J Clin Oncol* 2007;30:220-227.
270. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. *N Engl J Med* 2007;356:125-134.
271. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. *Cancer Res* 1997;57:4593-4599.
272. Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. *J Clin Oncol* 2007;25:4536-4541.
273. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. *N Engl J Med* 2003;349:427-434.
274. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. *Lancet* 2007;370:2103-2111.
275. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. *J Clin Oncol* 2008;26:5422-5428.
276. Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. *J Clin Oncol* 2009;27:4462-4468.
277. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. *Lancet Oncol* 2007;8:975-984.
278. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. *Lancet* 2011;378:1931-1939.
279. Hutson TE, Lesovoy V, Al-Shukri S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma: a randomised open-label phase 3 trial. *Lancet Oncol* 2013;14:1287-1294.
280. Barthelemy P, Hoch B, Chevreau C, et al. mTOR inhibitors in advanced renal cell carcinomas: From biology to clinical practice. *Crit Rev Oncol Hematol* 2013;88:42-56.
281. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. *J Clin Oncol* 2004;22:909-918.
282. Motzer RJ, Bukowski RM, Figlin RA, et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. *Cancer* 2008;113:1552-1558.
283. Motzer RJ, Barrios CH, Kim TM, et al. Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). *J Clin Oncol* 2013;31:abstr 4504.
284. Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. *J Clin Oncol* 2014;32:760-767.
285. Rini BI, Bellmunt J, Clancy J, et al. Randomized phase IIIB trial of temsirolimus and bevacizumab versus interferon and bevacizumab in metastatic renal cell carcinoma: results from INTORACT (LBA21). *Ann Oncol* 2012;23(suppl 9):ixe1-ixe30.
286. Ravaud A, Barrios CH, Anak Ö, et al. Randomized phase II study of first-line everolimus (EVE) + bevacizumab (BEV) versus interferon alfa-2A (IFN) + BEV in patients (PTS) with metastatic renal cell carcinoma (mRCC): record-2. Abstract #7830. *Ann Oncol* 2012;23:ixe1-ixe30.
287. Weight CJ, Miller DC, Campbell SC, et al. The management of a clinical T1b renal tumor in the presence of a normal contralateral kidney: the case for nephron sparing surgery. *J Urol* 2013;189:1198-1202.